Weilai Jin

Weilai Jin


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
FYFuqiang Yuan
Fuqiang Yuan
XHXu Han
Xu Han
MHMasha Huang
Masha Huang
YSYinglin Su
Yinglin Su
YZYiting Zhang
Yiting Zhang
LZLe Zhang
Le Zhang
The interactions between human milk and the regulation of innate immune homeostasis in newborns, and their impact on intestinal health, are not fully understood. This study aimed to explore the role of peptides in human milk extracellular vesicles (EVs) in this process. A comprehensive screening of peptides within human milk EVs was performed, leading to the identification of a beta-casein-derived peptide (CASB135-150). The effects of CASB135-150 on intestinal injury were evaluated in a rat necrotizing enterocolitis (NEC) model. Immunofluorescence analysis was used to determine its distribution, and its impact on NF-κB signaling and inflammation was studied in bone marrow-derived macrophages (BMDMs) and intestinal macrophages. Protein-protein interaction (PPI) analysis, single-cell RNA-seq (scRNA-seq), and co-immunoprecipitation (co-IP) experiments were conducted to explore the mechanism underlying CASB135-150 function. CASB135-150 significantly mitigated intestinal injury in the rat NEC model. Immunofluorescence analysis revealed that CASB135-150 could target intestinal macrophages and rapidly inhibited NF-κB signaling and reduced inflammation. ScRNA-seq analyses indicated a strong association between FHL2 and NEC development, and co-IP confirmed the interaction between CASB135-150 and FHL2. CASB135-150 disrupted the FHL2/TRAF6 complex, reducing TRAF6 protein levels. Mutation of key amino acids in CASB135-150 disrupted its interaction with FHL2 and abolished its ability to inhibit NF-κB signaling, which also prevented its protective effect in vivo. RNA-seq of intestinal tissue further highlighted the impact of CASB135-150 on the NF-κB signaling pathway. Our study identifies CASB135-150, a novel peptide in human milk EVs, that rapidly regulates macrophage inflammatory responses and protects against NEC-induced intestinal injury. These findings provide new insights into the role of human milk in modulating the infant immune system and intestinal health.

12 December 2024 in Molecular and Cellular Probes
Verified
Journal Article
Open access
LZLe Zhang
Le Zhang
JLJiahong Li
Jiahong Li
QWQiwen Wan
Qiwen Wan
CBChaozhi Bu
Chaozhi Bu
WJWeilai Jin
Weilai Jin
Wenhao ZhouWenhao Zhou
Wenhao Zhou
The therapeutic potential of intestinal stem cell-derived extracellular vesicles (ISCs-EVs) in necrotizing enterocolitis (NEC) remains largely unexplored. This research aims to investigate the therapeutic effects of ISCs-EVs on NEC. Lgr5-positive ISCs were screened from the small intestine of mice by flow cytometry, and ISCs-EVs were isolated by density gradient centrifugation. Subsequently, ISCs-EVs were identified through transmission electron microscopy, nanoparticle tracking analysis, and western blotting. Subsequently, we evaluated the efficacy of ISCs-EVs in a mouse model of NEC and found that they enhanced survival (more than 20 %), reduced intestinal damage (restore the number of intestinal crypts and decrease the expression of MPO and cleaved-caspase 3 in intestinal tissues), promoted angiogenesis (the mRNA expression of VEGF was increased by approximately 35 %), and mitigated inflammation (decreased the level of MUC1, p-NF-κB, IL-6 and TNF-α). Furthermore, in vitro assessments demonstrated that ISCs-EVs reduced apoptosis (P < 0.01) and stimulated proliferation (P < 0.05) of IEC-6 cells, while enhancing mucin secretion in LS174T cells. In summary, our study provides a comprehensive assessment of the therapeutic effects of ISCs-EVs on NEC, using both animal and cell models. This highlights their potential for use in NEC treatment.

4 October 2025 in iScience
Verified
Journal Article
Open access
RYRu Yan
Ru Yan
HZHonglian Zhang
Honglian Zhang
PZPan Zhang
Pan Zhang
MLMingyue Lv
Mingyue Lv
YPYuhan Pu
Yuhan Pu
YZYahui Zhou
Yahui Zhou
Bioactive components in breast milk offer a new therapeutic strategy for bronchopulmonary dysplasia (BPD). While osteopontin (OPN) is supplemented in formula to promote neonatal growth, the therapeutic role of its derived peptide, SVVYGLR (SV), in BPD remains unexplored. This study aimed to elucidate SV’s therapeutic mechanisms in BPD. The results revealed that SV significantly enhances cell viability, inhibits hyperoxia/LPS-induced apoptosis, and repairs alveolar epithelial injury. Molecularly, SV restores mitochondrial integrity, upregulates the anti-apoptotic protein BCL-2, and downregulates the pro-apoptotic protein Bax. In vivo experiments showed SV reduced hyperoxia/LPS-triggered BPD-like injury, evidenced by neonatal mice gaining weight, improved lung histology, and increased alveolar counts and septal thickness. Preliminary mechanistic studies revealed that SV interacts with KIF5B and enhances its binding to mitochondria. In conclusion, SV improves BPD by repairing mitochondrial damage and inhibiting apoptosis via KIF5B interaction. This study identified new potential targets and therapeutic strategies for BPD management.